181 related articles for article (PubMed ID: 1417929)
1. Studies of in vivo iron mobilization by chelators in the ferrocene-loaded rat.
Florence A; Ward RJ; Peters TJ; Crichton RR
Biochem Pharmacol; 1992 Sep; 44(6):1023-7. PubMed ID: 1417929
[TBL] [Abstract][Full Text] [Related]
2. Antioxidant and free radical scavenging activities of the iron chelators pyoverdin and hydroxypyrid-4-ones in iron-loaded hepatocyte cultures: comparison of their mechanism of protection with that of desferrioxamine.
Morel I; Cillard J; Lescoat G; Sergent O; Pasdeloup N; Ocaktan AZ; Abdallah MA; Brissot P; Cillard P
Free Radic Biol Med; 1992 Nov; 13(5):499-508. PubMed ID: 1334028
[TBL] [Abstract][Full Text] [Related]
3. Subcellular distribution of desferrioxamine and hydroxypyridin-4-one chelators in K562 cells affects chelation of intracellular iron pools.
Hoyes KP; Porter JB
Br J Haematol; 1993 Oct; 85(2):393-400. PubMed ID: 8280612
[TBL] [Abstract][Full Text] [Related]
4. Iron chelation studies using desferrioxamine and the potential oral chelator, 1,2-dimethyl-3-hydroxypyrid-4-one, in normal and iron loaded rats.
Kontoghiorghes GJ; Sheppard L; Hoffbrand AV; Charalambous J; Tikerpae J; Pippard MJ
J Clin Pathol; 1987 Apr; 40(4):404-8. PubMed ID: 3584483
[TBL] [Abstract][Full Text] [Related]
5. Biochemical and biophysical investigations of the ferrocene-iron-loaded rat. An animal model of primary haemochromatosis.
Ward RJ; Florence AL; Baldwin D; Abiaka C; Roland F; Ramsey MH; Dickson DP; Peters TJ; Crichton RR
Eur J Biochem; 1991 Dec; 202(2):405-10. PubMed ID: 1761043
[TBL] [Abstract][Full Text] [Related]
6. Ability of the orally effective iron chelators dimethyl- and diethyl-hydroxypyrid-4-one and of deferoxamine to restore sarcolemmal thiolic enzyme activity in iron-loaded heart cells.
Link G; Pinson A; Hershko C
Blood; 1994 May; 83(9):2692-7. PubMed ID: 8167347
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of iron toxicity in rat and human hepatocyte cultures by the hydroxypyridin-4-ones CP20 and CP94.
Chenoufi N; Hubert N; Loréal O; Morel I; Pasdeloup N; Cillard J; Brissot P; Lescoat G
J Hepatol; 1995 Aug; 23(2):166-73. PubMed ID: 7499788
[TBL] [Abstract][Full Text] [Related]
8. A comparison of the iron-clearing properties of 1,2-dimethyl-3-hydroxypyrid-4-one, 1,2-diethyl-3-hydroxypyrid-4-one, and deferoxamine.
Bergeron RJ; Streiff RR; Wiegand J; Luchetta G; Creary EA; Peter HH
Blood; 1992 Apr; 79(7):1882-90. PubMed ID: 1558978
[TBL] [Abstract][Full Text] [Related]
9. An animal model of iron overload and its application to study hepatic ferritin iron mobilization by chelators.
Longueville A; Crichton RR
Biochem Pharmacol; 1986 Nov; 35(21):3669-78. PubMed ID: 3778498
[TBL] [Abstract][Full Text] [Related]
10. Effects of chelators on iron uptake and release by the brain in the rat.
Crowe A; Morgan EH
Neurochem Res; 1994 Jan; 19(1):71-6. PubMed ID: 8139766
[TBL] [Abstract][Full Text] [Related]
11. Exploring the "iron shuttle" hypothesis in chelation therapy: effects of combined deferoxamine and deferiprone treatment in hypertransfused rats with labeled iron stores and in iron-loaded rat heart cells in culture.
Link G; Konijn AM; Breuer W; Cabantchik ZI; Hershko C
J Lab Clin Med; 2001 Aug; 138(2):130-8. PubMed ID: 11477380
[TBL] [Abstract][Full Text] [Related]
12. Comparative study of the protective effect between deferoxamine and deferiprone on chronic iron overload induced cardiotoxicity in rats.
Emara AM; El Kelany RS; Moustafa KA
Hum Exp Toxicol; 2006 Jul; 25(7):375-85. PubMed ID: 16898166
[TBL] [Abstract][Full Text] [Related]
13. Chelation of aluminium by combining DFO and L1 in rats.
Blanusa M; Prester L; Varnai VM; Pavlović D; Kostial K; Jones MM; Singh PK
Toxicology; 2000 Jul; 147(3):151-6. PubMed ID: 10924797
[TBL] [Abstract][Full Text] [Related]
14. Metabolism of iron from (3,5,5-trimethylhexanoyl)ferrocene in rats. A dietary model for severe iron overload.
Nielsen P; Heinrich HC
Biochem Pharmacol; 1993 Jan; 45(2):385-91. PubMed ID: 8435091
[TBL] [Abstract][Full Text] [Related]
15. Effects of desferrithiocin and its derivatives on peripheral iron and striatal dopamine and 5-hydroxytryptamine metabolism in the ferrocene-loaded rat.
Dexter DT; Ward RJ; Florence A; Jenner P; Crichton RR
Biochem Pharmacol; 1999 Jul; 58(1):151-5. PubMed ID: 10403528
[TBL] [Abstract][Full Text] [Related]
16. EPR study of antioxidant activity of the iron chelators pyoverdin and hydroxypyrid-4-one in iron-loaded hepatocyte culture: comparison with that of desferrioxamine.
Morel I; Sergent O; Cogrel P; Lescoat G; Pasdeloup N; Brissot P; Cillard P; Cillard J
Free Radic Biol Med; 1995 Feb; 18(2):303-10. PubMed ID: 7744315
[TBL] [Abstract][Full Text] [Related]
17. Brain iron in the ferrocene-loaded rat: its chelation and influence on dopamine metabolism.
Ward RJ; Dexter D; Florence A; Aouad F; Hider R; Jenner P; Crichton RR
Biochem Pharmacol; 1995 Jun; 49(12):1821-6. PubMed ID: 7598744
[TBL] [Abstract][Full Text] [Related]
18. Comparative efficacy and toxicity of desferrioxamine, deferiprone and other iron and aluminium chelating drugs.
Kontoghiorghes GJ
Toxicol Lett; 1995 Oct; 80(1-3):1-18. PubMed ID: 7482575
[TBL] [Abstract][Full Text] [Related]
19. Selection of a new generation of orally active alpha-ketohydroxypyridine iron chelators intended for use in the treatment of iron overload.
Kontoghiorghes GJ; Barr J; Nortey P; Sheppard L
Am J Hematol; 1993 Apr; 42(4):340-9. PubMed ID: 8493983
[TBL] [Abstract][Full Text] [Related]
20. In vivo and in vitro effects of 3-hydroxypyridin-4-one chelators on murine hemopoiesis.
Hoyes KP; Jones HM; Abeysinghe RD; Hider RC; Porter JB
Exp Hematol; 1993 Jan; 21(1):86-92. PubMed ID: 8417963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
